BioMarin: Settled Patent Dispute with Ascendis Pharma Brings Stable Cash Flows Until 2030!
Reading Time: 3 minutes
BioMarin achieves a far-reaching settlement in the patent dispute over the drug Yuviwel with Ascendis Pharma. The compromise secures BioMarin revenue shares of up to 20% in defined key markets until May 2030. The agreement strengthens the business model focused on rare genetic diseases and reduces legal risks. Focus on Rare Genetic Diseases BioMarin Pharmaceutical (BMRN) focuses on the development of therapies for patients with rare genetic diseases. The business model is based on identifying niche markets with high medical need. A key...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
